ERbeta Agonists for treatment of progressive MS
Posted: Fri Sep 13, 2013 2:24 am
Karo Bio receives funding from the National MS Society to develop ERbeta Agonists for treatment of progressive MS
Karo Bio AB has been awarded $0,5 million from the National Multiple Sclerosis Society through Fast Forward to develop a novel treatment – ERbeta agonists -- for progressive forms of Multiple Sclerosis (MS). The funds will finance the further preclinical development of Karo Bio’s advanced compounds...... Read More - http://www.ms-uk.org/emergingtherapies
Karo Bio AB has been awarded $0,5 million from the National Multiple Sclerosis Society through Fast Forward to develop a novel treatment – ERbeta agonists -- for progressive forms of Multiple Sclerosis (MS). The funds will finance the further preclinical development of Karo Bio’s advanced compounds...... Read More - http://www.ms-uk.org/emergingtherapies